Which agents can be used to treat heart failure with preserved ejection fraction (HFpEF)?

Heart failure with preserved ejection fraction (HFpEF) is a condition where the heart can pump blood effectively but has problems with relaxation and filling due to stiffness. Management of HFpEF often requires addressing the underlying conditions contributing to heart failure, such as hypertension and fluid overload.

ACE inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs) play a significant role in the treatment of patients with HFpEF. They help manage hypertension and reduce afterload, leading to improved symptoms and possibly better outcomes. These agents work by promoting vasodilation and helping to decrease the workload on the heart, which is particularly beneficial in patients with preserved ejection fraction as it can help alleviate symptoms of heart failure.

In contrast, while beta blockers can also be used in HFpEF, they are primarily indicated in specific scenarios, such as when there is an associated component of heart failure with reduced ejection fraction or in cases of arrhythmias. Corticosteroids, on the other hand, are not standard treatment for HFpEF and can lead to additional complications such as fluid retention. Therefore, the correct approach focuses on the use of ACE inhibitors and ARBs, highlighting their importance in managing the condition effectively.